These research results are from a retrospective, real-world, observational study assessing the risk of non-infectious uveitis among patients newly exposed to Remicade® and alternative for Remicade®-indicated conditions. This web-based application provides an interactive platform to explore all analysis results and validity diagnostics generated as part of this study, as a supplement to the full manuscript
Abstract:
Background: Autoimmune disorders have primary manifestations such as joint pain and bowel inflammation but can also have secondary manifestations such as non-infectious uveitis (NIU). A regulatory health authority raised concerns after receiving spontaneous reports for NIU following exposure to Remicade®, a biologic therapy with multiple indications for which alternative therapies are available. In assessment of this clinical question, we applied validity diagnostics to support observational data causal inferences.
Methods: We assessed the risk of NIU among patients exposed to Remicade® compared to alternative biologics. Five databases, four study populations, and four analysis methodologies were used to estimate 80 potential treatment effects, with 20 pre-specified as primary. The study populations included inflammatory bowel conditions Crohn’s disease or ulcerative colitis (IBD), ankylosing spondylitis (AS), psoriatic conditions plaque psoriasis or psoriatic arthritis (PsO/PsA), and rheumatoid arthritis (RA). We conducted four analysis strategies intended to address limitations of causal estimation using observational data and applied four diagnostics with pre-specified quantitative rules to evaluate threats to validity from observed and unobserved confounding. We also qualitatively assessed post-propensity score matching representativeness, and bias susceptibility from outcome misclassification. We fit Cox proportional-hazards models, conditioned on propensity score-matched sets, to estimate the on-treatment risk of NIU among Remicade® initiators versus alternatives. Estimates from analyses that passed four validity tests were assessed.
Results: Of the 80 total analyses and the 20 analyses pre-specified as primary, 24% and 20% passed diagnostics, respectively. Among patients with IBD, we observed no evidence of increased risk for NIU relative to other similarly indicated biologics (pooled hazard ratio [HR] 0.75, 95% confidence interval [CI] 0.38-1.40). For patients with RA, we observed no increased risk relative to similarly indicated biologics, although results were imprecise (HR: 1.23, 95% CI 0.14-10.47).
Conclusion: We applied validity diagnostics on a heterogenous, observational setting to answer a specific research question. The results indicated that safety effect estimates from many analyses would be inappropriate to interpret as causal, given the data available and methods employed. Validity diagnostics should always be used to determine if the design and analysis are of sufficient quality to support causal inferences. The clinical implications of our findings on IBD suggests that, if an increased risk exists, it is unlikely to be greater than 40% given the 1.40 upper bound of the pooled HR confidence interval.
Below are links for study-related artifacts that have been made available as part of this study: